Advisors Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Advisors Asset Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$390K	Sell	24,309 -5,476	-18%	-$90.6K	0.01%	1038
2026 Q1	$552K	Buy	29,785 +5,301	+22%	+$93K	0.01%	938
2025 Q4	$382K	Sell	24,484 -17,940	-42%	-$256K	0.01%	1018
2025 Q3	$621K	Buy	42,424 +4,395	+12%	+$65.3K	0.01%	928
2025 Q2	$588K	Sell	38,029 -9,234	-20%	-$136K	0.01%	911
2025 Q1	$703K	Buy	47,263 +7,852	+20%	+$110K	0.01%	856
2024 Q4	$522K	Sell	39,411 -11,815	-23%	-$162K	0.01%	913
2024 Q3	$728K	Buy	51,226 +14,992	+41%	+$213K	0.01%	814
2024 Q2	$469K	Sell	36,234 -13,547	-27%	-$179K	0.01%	915
2024 Q1	$691K	Buy	49,781 +3,315	+7%	+$48.2K	0.01%	826
2023 Q4	$663K	Sell	46,466 -17,410	-27%	-$247K	0.01%	820
2023 Q3	$988K	Buy	63,876 +6,628	+12%	+$103K	0.02%	724
2023 Q2	$899K	Sell	57,248 -19,710	-26%	-$323K	0.02%	777
2023 Q1	$1.27M	Buy	76,958 +7,485	+11%	+$119K	0.03%	679
2022 Q4	$1.08M	Sell	69,473 -7,887	-10%	-$110K	0.02%	722
2022 Q3	$1M	Buy	77,360 +8,940	+13%	+$124K	0.02%	723
2022 Q2	$961K	Buy	+68,420	New	+$977K	0.02%	764
2022 Q1	–	Sell	-59,563	Closed	-$812K	–	1159
2021 Q4	$812K	Sell	59,563 -3,321	-5%	-$46.6K	0.01%	873
2021 Q3	$1.03M	Buy	62,884 +9,277	+17%	+$156K	0.02%	809
2021 Q2	$902K	Buy	53,607 +9,811	+22%	+$167K	0.01%	864
2021 Q1	$800K	Buy	43,796 +19,268	+79%	+$347K	0.01%	886
2020 Q4	$446K	Buy	24,528 +7,650	+45%	+$134K	0.01%	1004
2020 Q3	$301K	Buy	16,878 +12,024	+248%	+$219K	0.01%	1064
2020 Q2	$87K	Buy	+4,854	New	+$87.1K	﹤0.01%	1328

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Advisors Asset Management's TAK Position: Q2 2026 in Review

Advisors Asset Management reduced its Takeda Pharmaceutical (TAK) stake by 18% in Q2 2026, selling an estimated $90.6K and leaving 24,309 shares worth $390K. The position accounts for 0.01% of the portfolio, ranked #1038.

Advisors Asset Management first reported a position in TAK in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.27M in Q1 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Advisors Asset Management held 24,309 shares of Takeda Pharmaceutical worth $390K as of Q2 2026.
Advisors Asset Management sold 5,476 Takeda Pharmaceutical shares in Q2 2026, an estimated $90.6K.
Takeda Pharmaceutical made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1038 holding.
Advisors Asset Management first reported a position in Takeda Pharmaceutical in Q2 2020 and has held it in 24 quarters since.
Advisors Asset Management's Takeda Pharmaceutical position peaked at $1.27M in Q1 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.